Lipocine is trading at $1.74, down 10.10%, with no reliable report identifying a specific October 9 catalyst.
- The latest company announcement was Health Canada’s October 7 approval of TLANDO; it was not confirmed as the reason for the decline.
- The broader market and biotech sector were reported higher, offering no clear same-direction explanation for Lipocine’s drop.
- Volume and activity-level data were not provided.